Exploration of the dopamine transporter:: In vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane (PE2I)

被引:71
|
作者
Guilloteau, D
Emond, P
Baulieu, JL
Garreau, L
Frangin, Y
Pourcelot, L
Mauclaire, L
Besnard, JC
Chalon, S
机构
[1] INSERM, U316, Lab Biophys Med & Pharmaceut, F-37200 Tours, France
[2] Cis Bio Ind, F-91192 Gif Sur Yvette, France
关键词
dopamine transporter; cocaine; SPECT; tropane;
D O I
10.1016/S0969-8051(97)00224-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
For the diagnosis and follow-up of neurodegenerative diseases, many cocaine derivatives have been proposed as radioligands to explore the dopamine transporter. As none of them have all the criteria of specificity and kinetics for human use, we have developed a new derivative, (E)-N-(3-iodoprop-2-enyl)-2 beta- carbomethoxy-3 beta-(4'-methylphenyl)nortropane (PE2I), which displays promising properties. We report the characterization of PE2I in vitro on rat striatal membranes and in vitro in rats and in monkeys. PE2I had a high affinity (Kd = 0.09 +/- 0.01 nM) and high specificity for the dopamine transporter. In rats we observed a high accumulation in the striatum; by contrast, a very low fixation was measured in the cortex. Moreover, a preinjection of a saturating dose of GBR 12909 prevented the striatal accumulation of PE2I by 74%. These results confirmed the specificity of PE2I for the dopamine transporter. In vivo in monkeys, SPECT studies showed a high accumulation in striatum. Moreover, an equilibrium state was obtained 1 h after injection. PE2I seemed to be the most promising ligand for the dopamine transporter exploration by SPECT using a single-day protocol. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 28 条
  • [1] Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells
    Page, G
    Chalon, S
    Emond, P
    Maloteaux, JM
    Hermans, E
    NEUROCHEMISTRY INTERNATIONAL, 2002, 40 (02) : 105 - 113
  • [2] Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2β-carboxymethoxy-3β-(4′-methylphenyl)nortropane as a selective and potent inhibitor of the neuronal dopamine transporter
    Chalon, S
    Garreau, L
    Emond, P
    Zimmer, L
    Vilar, MP
    Besnard, JC
    Guilloteau, D
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 291 (02): : 648 - 654
  • [3] Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments
    Stepanov, Vladimir
    Schou, Magnus
    Jarv, Jaak
    Halldin, Christer
    APPLIED RADIATION AND ISOTOPES, 2007, 65 (03) : 293 - 300
  • [4] Synthesis of iodinated and radioiodinated (E)-N-(3-iodoprop-2-enyl)-2 beta-carbomethoxy-3 beta-(3',4'-dichlorophenyl) nortropane (beta-CDIT): A ligand for the dopamine transporter.
    Emond, P
    Boazi, M
    Duchene, A
    Chalon, S
    Besnard, JC
    Guilloteau, D
    Frangin, Y
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1997, 39 (09): : 757 - 772
  • [5] Synthesis and ligand binding of nortropane derivatives: N-substituted 2 beta-carbomethoxy-3 beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2 beta-carbomethoxy-3 beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter
    Emond, P
    Garreau, L
    Chalon, S
    Boazi, M
    Caillet, M
    Bricard, J
    Frangin, Y
    Mauclaire, L
    Besnard, JC
    Guilloteau, D
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (09) : 1366 - 1372
  • [6] Synthesis of (E)-N-(3-bromoprop-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl) nortropane (PE2Br) and radiolabelling of [76Br]PE2Br:: A potential ligand for exploration of the dopamine transporter by PET.
    Helfenbein, J
    Emond, P
    Loc'h, C
    Bottlaender, M
    Ottaviani, M
    Guilloteau, D
    Mazière, B
    Frangin, Y
    Chalon, S
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1999, 42 (06): : 581 - 588
  • [7] Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter
    Chalon, S
    Hall, H
    Saba, W
    Garreau, L
    Dollé, F
    Halldin, C
    Emond, P
    Bottlaender, M
    Deloye, JB
    Helfenbein, J
    Madelmont, JC
    Bodard, S
    Mincheva, Z
    Besnard, JC
    Guilloteau, D
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (01): : 147 - 152
  • [8] Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
    Fazio, Patrik
    Svenningsson, Per
    Forsberg, Anton
    Jonsson, Erik G.
    Amini, Nahid
    Nakao, Ryuji
    Nag, Sangram
    Halldin, Christer
    Farde, Lars
    Varrone, Andrea
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) : 714 - 720
  • [9] Rhodamine-labeled 2β-carbomethoxy-3β-(3,4-dichlorophenyl)- tropane analogues as high-affinity fluorescent probes for the dopamine transporter
    Cha, JH
    Zou, MF
    Adkins, EM
    Rasmussen, SGF
    Loland, CJ
    Schoenenberger, B
    Gether, U
    Newman, AH
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) : 7513 - 7516
  • [10] Comparison of 2β-Carbomethoxy-3β-(4-[18F]Fluorophenyl)Tropane and N-(3-[18F]Fluoropropyl)-2β-Carbomethoxy-3β-(4-Fluorophenyl)Nortropane, Tracers for Imaging Dopamine Transporter in Rat
    Päivi Marjamäki
    Merja Haaparanta
    Sarita Forsback
    Veronica Fagerholm
    Olli Eskola
    Tove Grönroos
    Teija Koivula
    Olof Solin
    Molecular Imaging and Biology, 2010, 12 : 269 - 277